Berlin-Chemie/A. Menarini Ceska republika s.r.o. is the Czech subsidiary of Berlin-Chemie within the Menarini Group, a long-established European pharmaceutical group. The company is responsible for the promotion, distribution and medical information of Berlin-Chemie and Menarini pharmaceutical products on the Czech market. The portfolio covers prescription medicines and consumer healthcare products in key therapeutic areas such as cardiovascular and metabolic diseases, diabetes, respiratory and pulmonary disorders, gastroenterology, pain management and rheumatology, allergy and cold remedies, and selected oncology and other specialised segments, complemented by over-the-counter brands. Operations are centred in Prague, while the company uses a network of wholesalers, pharmacies and healthcare institutions to reach patients nationwide, backed by regional headquarters and manufacturing capacities of Berlin-Chemie in Germany and the broader Menarini network in more than thirty countries in Central and Eastern Europe and the CIS region. Key assets include the internationally recognised Berlin-Chemie and Menarini brands, a diversified prescription and OTC portfolio, and strong relationships with healthcare professionals and institutions. Strategically, Berlin-Chemie/A. Menarini Ceska republika s.r.o. positions itself as an innovative and quality-driven partner in primary and specialist care, focusing on evidence-based therapies, compliance with stringent quality and regulatory standards, and long-term development of the Menarini product portfolio in the Czech Republic.
Headquarters
Budejovicka 778/3
Prague; The City of Prague;
Postal Code: 14000
Contact Details: Purchase the Berlin-Chemie/A.Menarini Ceska Republika S.R.O. report to view the information.
Website: https://www.berlin-chemie.cz
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service